The Cash-Pay GLP-1 and Peptide Revenue Model: What Practices Actually Earn

Medical practices exploring cash-pay medication programs often ask the same question: what will this actually earn? The economics of GLP-1 weight loss, peptide therapy, and TRT programs differ significantly from traditional insurance-based medicine, and the differences favor the practice owner.

This article breaks down the real numbers: revenue per patient, overhead costs, pharmacy margins, staff time, and net profit. Whether you are evaluating your first cash-pay program or optimizing an existing one, this analysis provides the financial framework for decision-making.

The Cash-Pay Model vs. Insurance-Based Revenue

Before diving into specific program economics, it helps to understand why cash-pay programs generate outsized returns relative to clinical time invested.

Insurance-Based Revenue Challenges

Traditional insurance-based practices face structural revenue constraints:

• Reimbursement rates are declining. Medicare and commercial payer reimbursements have not kept pace with practice costs. According to the American Medical Association, Medicare physician payment has declined approximately 26% in inflation-adjusted terms since 2001. The CMS Physician Fee Schedule continues to compress reimbursement rates year over year.
• Administrative overhead consumes revenue. Billing, coding, prior authorizations, claim denials, and appeals consume 15% to 25% of gross collections in most practices. A Medical Group Management Association (MGMA) benchmarking study found that administrative costs represent a growing share of practice expenses for insurance-dependent groups.
• Payment delays strain cash flow. Insurance reimbursement cycles of 30 to 90 days create cash flow gaps that require working capital.
• Volume requirements drive burnout. To maintain revenue targets, practices must see high patient volumes, leading to shorter visits and provider exhaustion.

Cash-Pay Revenue Advantages

Cash-pay specialty programs eliminate these constraints:

• You set the price. No fee schedules, no negotiated rates, no annual reductions.
• Payment is collected upfront. No claims, no denials, no 90-day receivables.
• Administrative costs are minimal. No coding, no billing department, no prior authorization staff.
• Recurring revenue builds over time. Patients on monthly protocols generate predictable, compounding revenue.
• Higher revenue per clinical hour. Fewer patients, more revenue, better care quality.

Revenue Per Patient by Program Type

The following ranges represent typical practice pricing based on market data from practices running these programs across the United States.

GLP-1 Weight Loss Programs: $250 to $500 Per Month

GLP-1 programs command the highest per-patient revenue due to strong patient demand and high perceived value. The GLP-1 receptor agonist market has seen explosive growth, with IQVIA research tracking prescription volume increases exceeding 300% since 2020.

Typical pricing structure:

• Monthly program fee: $250 to $500
• Includes: compounded medication, clinical oversight, monthly check-in, dosing adjustments
• Some practices charge a separate onboarding fee of $100 to $200 for initial consultation and lab review

Wholesale medication cost:

• Compounded semaglutide: $80 to $150 per month (varies by dose and pharmacy)
• Compounded tirzepatide: $100 to $200 per month (varies by dose and pharmacy)

Net margin per patient: $150 to $350 per month

Clinical time per patient: 5 to 15 minutes monthly (dose adjustments, check-ins)

At 50 active GLP-1 patients averaging $350 per month in program fees, a practice generates $17,500 in monthly recurring revenue. After pharmacy costs of approximately $5,000 to $7,500, net program revenue is $10,000 to $12,500 monthly from this single program.

Peptide Therapy Programs: $200 to $400 Per Month

Peptide therapy programs offer strong margins with excellent patient retention due to the ongoing nature of most protocols.

Typical pricing structure:

• Monthly program fee: $200 to $400
• Varies by peptide protocol (single peptide vs. combination protocols)
• Premium protocols (multi-peptide stacks) can reach $500 to $800 monthly

Wholesale medication cost:

• BPC-157: $30 to $60 per month
• CJC-1295/Ipamorelin: $50 to $100 per month
• Thymosin Alpha-1: $60 to $120 per month
• Multi-peptide protocols: $100 to $200 per month

Net margin per patient: $150 to $300 per month

Clinical time per patient: 5 to 10 minutes monthly

Peptide patients tend to have longer treatment durations than GLP-1 patients. Many remain on protocols for 6 to 12 months or cycle between protocols seasonally, creating strong lifetime value.

TRT Programs: $150 to $300 Per Month

Testosterone replacement therapy offers the highest patient lifetime value due to the indefinite treatment duration for most patients.

Typical pricing structure:

• Monthly program fee: $150 to $300
• Includes: testosterone compound, clinical monitoring, quarterly lab reviews
• Some practices charge separately for labs ($50 to $100 quarterly)

Wholesale medication cost:

• Compounded testosterone (cypionate or enanthate): $30 to $60 per month
• Ancillary medications (anastrozole, HCG if included): $20 to $40 per month

Net margin per patient: $100 to $200 per month

Clinical time per patient: 5 to 10 minutes monthly, 15 to 20 minutes quarterly for lab review

TRT patients are the stickiest cohort in cash-pay medicine. According to research published in the Journal of Clinical Endocrinology & Metabolism, most TRT patients remain on therapy indefinitely once stabilized. A TRT patient acquired today may generate revenue for 5 to 10 years or longer. For a step-by-step approach to launching this program type, see our guide to starting a TRT clinic.

Overhead and Operating Costs

Understanding the true cost structure is critical for accurate financial projections.

Platform and Technology Costs

Running a cash-pay specialty program requires infrastructure for patient intake, clinical review, prescribing, pharmacy integration, and fulfillment tracking.

Options and their costs:

1. Turn-key platform (Karpa Health model): $200 to $500 per month for the platform, which handles intake, AI clinical review, prescribing workflows, pharmacy routing, and fulfillment tracking. This is the most cost-effective approach for practices that want to launch quickly without building custom systems.

2. Cobbled-together tools: $300 to $800 per month across multiple subscriptions (EMR, telehealth, e-prescribing, CRM, forms). This approach requires more staff time to manage integrations and handoffs between systems.

3. Custom build: $10,000 to $50,000 upfront plus ongoing maintenance. Only justified at very high patient volumes (500+ patients).

Staff Time and Labor Costs

The biggest variable cost in any program is staff time per patient interaction.

Traditional (manual) workflow:

• Patient intake and form review: 15 to 20 minutes
• Clinical review and chart documentation: 10 to 15 minutes
• Prescription writing and pharmacy communication: 5 to 10 minutes
• Follow-up scheduling and coordination: 5 to 10 minutes
• Total per new patient: 35 to 55 minutes
• Total per monthly follow-up: 15 to 25 minutes

Automated workflow (with AI triage and digital systems):

• Patient intake: automated (digital forms, self-service)
• Clinical review: 3 to 5 minutes (AI pre-review with provider approval)
• Prescribing: 1 to 2 minutes (one-click prescribing)
• Follow-up: automated scheduling and check-in
• Total per new patient: 10 to 15 minutes
• Total per monthly follow-up: 3 to 7 minutes

The difference in staff time directly translates to capacity. A practice using manual workflows might handle 30 to 50 cash-pay patients before needing additional staff. With automation, the same team can manage 150 to 300 patients.

Marketing and Patient Acquisition Costs

Patient acquisition costs vary widely by channel and market:

• Google Ads (search): $50 to $150 per acquired patient
• Social media advertising: $30 to $100 per acquired patient
• Referrals from existing patients: $0 to $25 per acquired patient (referral incentive)
• Content marketing and SEO: Low per-patient cost at scale, but requires 3 to 6 months to build

For most practices, blended patient acquisition cost settles between $50 and $100 per patient. Given that patient lifetime value ranges from $1,800 to $6,000+ (depending on program and retention), the return on marketing spend is compelling. Research from the Physicians Foundation surveys shows that cash-pay and direct-pay models are growing across specialties as both physicians and patients seek alternatives to traditional insurance billing.

Building a Revenue Model: Example Scenarios

Scenario 1: New Practice, First 90 Days

A practice launches with GLP-1 and peptide programs:

• Month 1: 8 patients acquired (5 GLP-1, 3 peptide)
• Month 2: 15 cumulative patients (10 GLP-1, 5 peptide)
• Month 3: 25 cumulative patients (15 GLP-1, 10 peptide)

Month 3 revenue:

• 15 GLP-1 patients x $350 average = $5,250
• 10 peptide patients x $275 average = $2,750
• Total monthly revenue: $8,000

Month 3 costs:

• Pharmacy wholesale: $2,400
• Platform: $350
• Marketing: $1,000
• Total costs: $3,750

Month 3 net profit: $4,250

Scenario 2: Established Practice, 12 Months In

A practice running GLP-1, peptides, and TRT after one year:

• 60 GLP-1 patients x $375 average = $22,500
• 40 peptide patients x $300 average = $12,000
• 35 TRT patients x $200 average = $7,000
• Total monthly revenue: $41,500

Monthly costs:

• Pharmacy wholesale: $11,000
• Platform: $500
• Staff (one part-time coordinator): $2,500
• Marketing: $2,000
• Total costs: $16,000

Monthly net profit: $25,500

This represents $306,000 in annual net profit from programs that require approximately 15 to 20 hours of clinical time per week.

Why Cash-Pay Outperforms Insurance: A Direct Comparison

Consider a family medicine practice generating $600,000 in annual revenue from insurance-based services:

The cash-pay model generates comparable net revenue with a fraction of the patient volume and clinical time. Data from the HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE) shows that administrative complexity in insurance-based medicine continues to rise, further widening the efficiency gap between cash-pay and traditional models. This is not an argument for abandoning insurance-based medicine entirely, but rather for adding cash-pay programs as a high-margin revenue layer.

Key Metrics to Track

Practices running successful cash-pay programs monitor these metrics:

Revenue Metrics

• Monthly recurring revenue (MRR): Total active patient revenue per month
• Average revenue per patient (ARPP): Total revenue divided by active patients
• Patient lifetime value (LTV): Average revenue generated over the full patient relationship
• Revenue per clinical hour: Total revenue divided by provider hours spent on the program

Operational Metrics

• Patient acquisition cost (CAC): Marketing spend divided by new patients acquired
• LTV to CAC ratio: Should be 10:1 or higher for cash-pay programs
• Churn rate: Percentage of patients discontinuing each month (target under 8%)
• Time to first prescription: Days from patient inquiry to first medication shipped

Margin Metrics

• Gross margin: Revenue minus pharmacy wholesale costs
• Net margin: Revenue minus all program-related costs
• Contribution margin per patient: Net revenue per patient after all variable costs

How Karpa Health Simplifies the Operational Side

The revenue model is compelling, but the execution complexity is what stops most practices from launching. Managing patient intake, clinical review, prescribing, pharmacy coordination, and fulfillment tracking across dozens or hundreds of patients requires infrastructure.

Karpa Health provides the operational backbone that makes these economics achievable:

• AI-powered clinical review reduces provider time per patient from 15+ minutes to 3 to 5 minutes
• One-click prescribing eliminates manual prescription writing and pharmacy portal navigation
• Integrated pharmacy routing automatically sends prescriptions to the optimal pharmacy partner, including Empower Pharmacy and other vetted compounding partners
• Automated patient intake handles forms, medical history, and consent digitally
• Fulfillment tracking keeps patients informed without staff intervention
• White-label capability lets your practice brand the entire patient experience

The platform transforms the cash-pay revenue model from theoretically attractive to operationally achievable, even for practices without dedicated program staff.

Getting Started

For practices evaluating whether to add cash-pay programs, the financial case is clear. The question is not whether these programs are profitable, but how quickly you can build patient volume.

The practices that succeed focus on three priorities:

1. Launch quickly. Every month of delay is lost recurring revenue. Use a turn-key platform rather than spending months building custom systems.
2. Start with one or two programs. Most practices launch with GLP-1 weight loss or peptide therapy, then add TRT once the workflow is established.
3. Invest in patient acquisition. The economics reward scale. Allocate marketing budget from day one and track acquisition cost relative to patient lifetime value.

The cash-pay medication model represents one of the clearest opportunities in modern practice economics. The practices that move first will build patient bases and recurring revenue that compound over time.